Ang Li1, David A Garcia2, Gary H Lyman3, Marc Carrier4. 1. Division of Hematology, University of Washington School of Medicine, Seattle, WA, United States. Electronic address: ali2015@uw.edu. 2. Division of Hematology, University of Washington School of Medicine, Seattle, WA, United States. 3. Divisions of Public Health Sciences and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Division of Medical Oncology, University of Washington School of Medicine, Seattle, WA, United States. 4. Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Abstract
INTRODUCTION: It is unclear if direct oral anticoagulants (DOACs) are effective and safe alternatives to low-molecular-weight heparin (LMWHs) for the treatment of cancer-associated venous thromboembolism (VTE). We aim to synthesize existing literature that compared DOACs versus LMWHs in this high-risk population. MATERIALS AND METHODS: We conducted a systematic review using EMBASE, MEDLINE and CENTRAL for all observational studies and randomized controlled trials (RCTs) (PROSPERO: CRD42017080898). Two authors independently reviewed study eligibility, extracted data, and assessed bias. Primary outcomes included 6-month recurrent VTE and major bleeding. Secondary outcomes included clinically relevant non-major bleeding (CRNMB) and mortality. RESULTS: We screened 426 articles, reviewed 25 in full-text, and selected 13 and 2 for qualitative and quantitative synthesis, respectively. Based on a meta-analysis of the 2 RCTs, DOACs had lower 6-month recurrent VTE (42/725) when compared to LMWH (64/727) (RR: 0.65 (0.42-1.01)). However, DOACs had higher major bleeding (40/725) when compared to LMWH (23/727) (RR 1.74 (1.05-2.88)). Similarly, CRNMB was higher (RR 2.31 (0.85-6.28)) for patients receiving DOACs. There was no difference in mortality (RR 1.03 (0.85-1.26)). Observational studies were heterogeneous with high risks of bias but showed recurrent VTE rates consistent with the meta-analysis. CONCLUSIONS: DOACs were more effective than LMWHs to prevent recurrent VTE but were associated with a significantly increased risk of major bleeding as well as a trend toward more CRNMB. The absolute risk differences were small (2-3%) for both primary outcomes and may reflect better compliance with DOACs than LMWHs.
INTRODUCTION: It is unclear if direct oral anticoagulants (DOACs) are effective and safe alternatives to low-molecular-weight heparin (LMWHs) for the treatment of cancer-associated venous thromboembolism (VTE). We aim to synthesize existing literature that compared DOACs versus LMWHs in this high-risk population. MATERIALS AND METHODS: We conducted a systematic review using EMBASE, MEDLINE and CENTRAL for all observational studies and randomized controlled trials (RCTs) (PROSPERO: CRD42017080898). Two authors independently reviewed study eligibility, extracted data, and assessed bias. Primary outcomes included 6-month recurrent VTE and major bleeding. Secondary outcomes included clinically relevant non-major bleeding (CRNMB) and mortality. RESULTS: We screened 426 articles, reviewed 25 in full-text, and selected 13 and 2 for qualitative and quantitative synthesis, respectively. Based on a meta-analysis of the 2 RCTs, DOACs had lower 6-month recurrent VTE (42/725) when compared to LMWH (64/727) (RR: 0.65 (0.42-1.01)). However, DOACs had higher major bleeding (40/725) when compared to LMWH (23/727) (RR 1.74 (1.05-2.88)). Similarly, CRNMB was higher (RR 2.31 (0.85-6.28)) for patients receiving DOACs. There was no difference in mortality (RR 1.03 (0.85-1.26)). Observational studies were heterogeneous with high risks of bias but showed recurrent VTE rates consistent with the meta-analysis. CONCLUSIONS:DOACs were more effective than LMWHs to prevent recurrent VTE but were associated with a significantly increased risk of major bleeding as well as a trend toward more CRNMB. The absolute risk differences were small (2-3%) for both primary outcomes and may reflect better compliance with DOACs than LMWHs.
Authors: Saeed K Alzghari; Susan E Seago; Jessica E Garza; Yasmeen F Hashimie; Kimberly A Baty; Martha F Evans; Courtney Shaver; Jon D Herrington Journal: J Oncol Pharm Pract Date: 2017-07-16 Impact factor: 1.809
Authors: Marc Carrier; Chris Cameron; Aurélien Delluc; Lana Castellucci; Alok A Khorana; Agnes Y Y Lee Journal: Thromb Res Date: 2014-10-08 Impact factor: 3.944
Authors: Dominique Farge; Henri Bounameaux; Benjamin Brenner; Francis Cajfinger; Philippe Debourdeau; Alok A Khorana; Ingrid Pabinger; Susan Solymoss; James Douketis; Ajay Kakkar Journal: Lancet Oncol Date: 2016-10 Impact factor: 41.316
Authors: Agnes Y Y Lee; Pieter W Kamphuisen; Guy Meyer; Rupert Bauersachs; Mette S Janas; Mikala F Jarner; Alok A Khorana Journal: JAMA Date: 2015-08-18 Impact factor: 56.272
Authors: Gary E Raskob; Nick van Es; Peter Verhamme; Marc Carrier; Marcello Di Nisio; David Garcia; Michael A Grosso; Ajay K Kakkar; Michael J Kovacs; Michele F Mercuri; Guy Meyer; Annelise Segers; Minggao Shi; Tzu-Fei Wang; Erik Yeo; George Zhang; Jeffrey I Zwicker; Jeffrey I Weitz; Harry R Büller Journal: N Engl J Med Date: 2017-12-12 Impact factor: 91.245
Authors: Jonathan Ac Sterne; Miguel A Hernán; Barnaby C Reeves; Jelena Savović; Nancy D Berkman; Meera Viswanathan; David Henry; Douglas G Altman; Mohammed T Ansari; Isabelle Boutron; James R Carpenter; An-Wen Chan; Rachel Churchill; Jonathan J Deeks; Asbjørn Hróbjartsson; Jamie Kirkham; Peter Jüni; Yoon K Loke; Theresa D Pigott; Craig R Ramsay; Deborah Regidor; Hannah R Rothstein; Lakhbir Sandhu; Pasqualina L Santaguida; Holger J Schünemann; Beverly Shea; Ian Shrier; Peter Tugwell; Lucy Turner; Jeffrey C Valentine; Hugh Waddington; Elizabeth Waters; George A Wells; Penny F Whiting; Julian Pt Higgins Journal: BMJ Date: 2016-10-12
Authors: A J Muñoz Martín; E Gallardo Díaz; I García Escobar; R Macías Montero; V Martínez-Marín; V Pachón Olmos; P Pérez Segura; T Quintanar Verdúguez; M Salgado Fernández Journal: Clin Transl Oncol Date: 2020-01-24 Impact factor: 3.405
Authors: A Franco-Moreno; L Cabezón-Gutiérrez; M Palka-Kotlowsa; M Villamayor-Delgado; M García-Navarro Journal: J Thromb Thrombolysis Date: 2019-04 Impact factor: 2.300
Authors: Jan Beyer-Westendorf; Robert Klamroth; Stephan Kreher; Florian Langer; Axel Matzdorff; Hanno Riess Journal: Dtsch Arztebl Int Date: 2019-01-18 Impact factor: 5.594
Authors: Rasha Khatib; Stephanie Ross; Sean Alexander Kennedy; Ivan D Florez; Thomas L Ortel; Robby Nieuwlaat; Ignacio Neumann; Daniel M Witt; Sam Schulman; Veena Manja; Rebecca Beyth; Nathan P Clark; Wojtek Wiercioch; Holger J Schünemann; Yuqing Zhang Journal: Blood Adv Date: 2020-02-11